A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®)

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2026-02-06
DOI
https://doi.org/10.1080/14796694.2026.2613140
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®)

Michael Mauro, Dan Douer, Jerald Radich
Future Oncology
Chronic Myeloid Leukemia Treatments
article

A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®)

Michael Mauro, Dan Douer, Jerald Radich
article en

Abstract

No abstract available for this paper.
Future OncologyVol. 22(4)
University of Southern California (US), Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA), Memorial Sloan Kettering Cancer Center (US), Kettering University (US), Fred Hutch Cancer Center (US)
Zero hunger
Openalex Percentile: Top 62%
Chronic Myeloid Leukemia Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.